While the United States argues about rescheduling in courtrooms and hearing halls, the rest of the cannabis world is quietly getting on with business — and two developments this week show exactly where the global money and momentum are flowing. One is a Canadian company posting a record year by going all-in on international medical markets. The other is a German biopharma firm winning Europe's first prescription approval for a cannabis-based back-pain medicine. Read together, they tell you something important: the center of gravity in global cannabis is shifting toward medical and pharmaceutical-grade products, and the companies leaning into that shift are the ones thriving.
Aurora's record year is a strategy lesson
Start with the numbers, because they're genuinely strong in an industry where strong numbers have been scarce. Aurora Cannabis reported fiscal 2026 results with total net revenue up 11% to C$321 million, global medical cannabis revenue up 18% to C$288.6 million, and adjusted EBITDA up 32% to C$53.8 million. The company closed the year with C$164.7 million in cash and no debt — a balance sheet most cannabis operators can only envy.
What makes this notable isn't just the growth; it's how Aurora got there. The company has deliberately pivoted away from the consumer cannabis market — the crowded, price-compressed, low-margin world of recreational flower and pre-rolls — and toward international medical cannabis, with Germany and Poland as the primary engines. In April 2026 it completed the acquisition of Safari Flower Company, adding a 59,000-square-foot EU-GMP-certified facility, the kind of pharmaceutical-grade infrastructure that medical export markets demand.
This is the part operators everywhere should study. For years, the assumption was that consumer cannabis was the prize and medical was the boring, smaller sibling. Aurora's results invert that. By chasing higher-margin medical demand in markets with structured reimbursement and less ruinous price competition, it built a profitable, debt-free business while many consumer-focused competitors bled cash. Strategy, not just scale, is what's separating winners from the rest.
The lesson in Aurora's numbers isn't 'cannabis is back.' It's that focus beats sprawl — and medical markets reward the operators willing to build to pharmaceutical standards.
Europe just set a pharmaceutical precedent
The second development may matter even more in the long run. Vertanical, a German biopharmaceutical company, received marketing authorization in Germany and Austria for Exilby (VER-01), a full-spectrum cannabis extract for chronic lower back pain with a neuropathic component. It is Europe's first marketing authorization for a cannabis-based prescription medicine for back pain — a real pharmaceutical approval, not a wellness product or a medical-program workaround.
The trial data is what gives it weight. According to the company, two Phase 3 trials showed Exilby reduced pain more effectively than opioids, with greater tolerability and no evidence of dependence. In an era defined by the catastrophic costs of opioid addiction, a plant-derived medicine that outperforms opioids on pain without the dependence risk is exactly the kind of result that gets regulators and physicians to pay attention. A commercial launch is planned for September 2026, and Vertanical is pursuing approval with the UK's MHRA and has secured Breakthrough Therapy Designation from the U.S. FDA.
Why a German approval matters to an American audience
It's fair to ask why a back-pain drug approved in Germany should matter to a cannabis reader in New York. The answer is precedent and direction. For decades, the strongest argument against cannabis was that it lacked rigorous, pharmaceutical-grade evidence of medical efficacy. Approvals like Exilby chip away at that argument with exactly the kind of Phase 3, head-to-head, regulator-reviewed data that skeptics have demanded. Each one makes it harder to claim cannabis has 'no accepted medical use' — the very phrase at the heart of America's own Schedule I framework.
There's also a competitive and investment signal here. Capital flows toward legitimacy and margin, and both Aurora's results and Vertanical's approval point investors toward medical and pharmaceutical cannabis as the segment with the clearest path to durable profit. That has ripple effects on the whole industry, including the U.S. market that operators in New York compete in. The money and the credibility accumulating in medical cannabis abroad strengthen the broader case for reform at home.
The contrast worth sitting with
There's an irony in this week's news that's hard to miss. In the U.S., cannabis policy is tangled in litigation, with opponents asking a federal court to freeze even a modest, medical-only rescheduling. Meanwhile, Germany is approving cannabis medicines that beat opioids in clinical trials, and a Canadian company is posting record profits by serving European medical demand. The rest of the developed world is treating cannabis as a serious medical and commercial category while America debates the paperwork.
I don't point that out to score a political point — reform is genuinely hard, and the U.S. market is enormous and complicated in ways smaller markets aren't. But the contrast is instructive. The global trend line is clear, and it runs toward medical legitimacy, pharmaceutical standards, and international scale. The companies and countries that internalize that are pulling ahead. For U.S. operators, including those building New York's young market, the takeaway is that the future of this industry is being defined as much by clinical data and disciplined strategy as by any single courtroom or hearing room.
The bottom line
A record, debt-free year for Aurora and Europe's first cannabis back-pain drug approval are two faces of the same story: global cannabis is maturing into a medical and pharmaceutical industry, and the players leaning into that are winning. It's a useful counterweight to the noise of U.S. policy fights — a reminder that beyond the headlines, the science is advancing and the business is, in places, genuinely thriving. New York shoppers can keep tracking their own market's dispensaries and deals on High Today. For adults 21+. Not medical advice.